173 related articles for article (PubMed ID: 37932752)
21. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
[TBL] [Abstract][Full Text] [Related]
22. Controlled loading of albumin-drug conjugates ex vivo for enhanced drug delivery and antitumor efficacy.
Liu X; Mohanty RP; Maier EY; Peng X; Wulfe S; Looney AP; Aung KL; Ghosh D
J Control Release; 2020 Dec; 328():1-12. PubMed ID: 32798638
[TBL] [Abstract][Full Text] [Related]
23. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
[TBL] [Abstract][Full Text] [Related]
24. Preparation and anti-cancer evaluation of promiximab-MMAE, an anti-CD56 antibody drug conjugate, in small cell lung cancer cell line xenograft models.
Yu L; Yao Y; Wang Y; Zhou S; Lai Q; Lu Y; Liu Y; Zhang R; Wang R; Liu C; Gou L; Chen X; Yu Y; Chen Q; Yang J
J Drug Target; 2018 Dec; 26(10):905-912. PubMed ID: 29630426
[TBL] [Abstract][Full Text] [Related]
25. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor.
Bussing D; Sharma S; Li Z; Meyer LF; Shah DK
AAPS J; 2021 Apr; 23(3):56. PubMed ID: 33856579
[TBL] [Abstract][Full Text] [Related]
26. Selection of Payloads for Antibody-Drug Conjugates Targeting Ubiquitously Expressed Tumor-Associated Antigens: a Case Study.
Yao B; Gao X; Dan M; Yuan C; Hu X; Sun Z; Hui X; Liu B; Ouyang P; Chen G
AAPS J; 2022 May; 24(4):70. PubMed ID: 35624189
[TBL] [Abstract][Full Text] [Related]
27. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH
Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241
[TBL] [Abstract][Full Text] [Related]
28. CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy.
Khan T; Lyons NJ; Gough M; Kwah KKX; Cuda TJ; Snell CE; Tse BW; Sokolowski KA; Pearce LA; Adams TE; Rose SE; Puttick S; Pajic M; Adams MN; He Y; Hooper JD; Kryza T
Theranostics; 2022; 12(16):6915-6930. PubMed ID: 36276654
[No Abstract] [Full Text] [Related]
29. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
[TBL] [Abstract][Full Text] [Related]
30. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
[No Abstract] [Full Text] [Related]
31. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
32. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
[TBL] [Abstract][Full Text] [Related]
33. Half-life extension of single-domain antibody-drug conjugates by albumin binding moiety enhances antitumor efficacy.
Li Q; Kong Y; Zhong Y; Huang A; Ying T; Wu Y
MedComm (2020); 2024 May; 5(5):e557. PubMed ID: 38737471
[TBL] [Abstract][Full Text] [Related]
34. Targeting Trop2 in solid tumors: a look into structures and novel epitopes.
Liu X; Li J; Deng J; Zhao J; Zhao G; Zhang T; Jiang H; Liang B; Xing D; Wang J
Front Immunol; 2023; 14():1332489. PubMed ID: 38179054
[TBL] [Abstract][Full Text] [Related]
35. An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer.
Bourillon L; Bourgier C; Gaborit N; Garambois V; Llès E; Zampieri A; Ogier C; Jarlier M; Radosevic-Robin N; Orsetti B; Delpech H; Theillet C; Colombo PE; Azria D; Pèlegrin A; Larbouret C; Chardès T
Int J Cancer; 2019 Oct; 145(7):1838-1851. PubMed ID: 30882895
[TBL] [Abstract][Full Text] [Related]
36. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
[TBL] [Abstract][Full Text] [Related]
37. TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer.
Cortesi M; Zanoni M; Maltoni R; Ravaioli S; Tumedei MM; Pirini F; Bravaccini S
Expert Opin Ther Targets; 2022 Jul; 26(7):593-602. PubMed ID: 35962580
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model.
Wu G; Li L; Liu M; Chen C; Wang G; Jiang Z; Qin Y; He L; Li H; Cao J; Gu H
Cancer Cell Int; 2022 Dec; 22(1):417. PubMed ID: 36572921
[TBL] [Abstract][Full Text] [Related]
39. Theranostic application of
Li C; Liu J; Yang X; Yang Q; Huang W; Zhang M; Zhou D; Wang R; Gong J; Miao Q; Kang L; Yang J
Eur J Nucl Med Mol Imaging; 2022 Dec; 50(1):168-183. PubMed ID: 36063202
[TBL] [Abstract][Full Text] [Related]
40. A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.
Wang X; Sheng W; Wang Y; Li L; Li Y; Zhang S; Liu X; Chen S; Zhen Y
Mol Pharm; 2018 Jun; 15(6):2403-2412. PubMed ID: 29757658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]